{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:36:44Z","timestamp":1780414604577,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001024","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2004,7,19]],"date-time":"2004-07-19T00:00:00Z","timestamp":1090195200000}}],"reference-count":43,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001024.pub2","type":"journal-article","created":{"date-parts":[[2004,7,21]],"date-time":"2004-07-21T07:08:53Z","timestamp":1090393733000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tamoxifen for hepatocellular carcinoma"],"prefix":"10.1002","author":[{"given":"Anna K","family":"Nowak","sequence":"first","affiliation":[{"name":"Sir Charles Gardiner Hospital and University of Western Australia; Department of Medical Oncology; B Block, Hospital Avenue Nedlands Perth WA Australia 6099"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Findlay","sequence":"additional","affiliation":[{"name":"Wellington Hospital; Medical Oncology; Private Bag 7902 Wellington South New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Culjak","sequence":"additional","affiliation":[{"name":"Faculty of Information Technology; Department of Information Systemes; Building 10, City Campus University of Technology Sydney NSW Australia 2007"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R","family":"Stockler","sequence":"additional","affiliation":[{"name":"University of Sydney; NHMRC Clinical Trials Centre and Sydney Cancer Centre; GH6 RPAH Missenden Road Camperdown NSW Australia 2050"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,19]]},"reference":[{"key":"10.1002\/14651858.CD001024.pub2-BIB0001|cit1","unstructured":"Barbare JC Milan C Bouch\u00e9 O Raoul JL Rougier P Bommelear G Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen: a phase III trial in 420 patients Proceedings of ASCO 2002 Abstract 551"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Bruix J Castells A Bru C Ayuso MC Boix L Roca M Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen (TMX). Preliminary results of a randomized double blind placebo-controlled trial Journal of Hepatology 1994 S152 00220572","DOI":"10.1016\/S0168-8278(05)81229-2"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Bruix J Castells A Bru C Ayuso MC Boix L Roca M Treatment of advanced hepatocellular carcinoma with tamoxifen. Results of a randomized double blind placebo controlled trial in 120 patients Hepatology 1994 279A 00220573","DOI":"10.1016\/0016-5085(95)90402-6"},{"issue":"3","key":"10.1002\/14651858.CD001024.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0016-5085(95)90402-6","article-title":"Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients","volume":"109","author":"Castells","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0005|cit5","first-page":"221","article-title":"Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients","volume":"20","author":"Castells","year":"1996","journal-title":"Gastroenterologie Clinique et Biologique"},{"issue":"5","key":"10.1002\/14651858.CD001024.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1053\/jhep.2002.36824","article-title":"High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial","volume":"36","author":"Chow","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0007|cit7","unstructured":"Chow PK Tan CK Tai BC Machin D Soo KC High dose tamoxifen versus placebo for inoperable hepatocellular carcinoma: Asia-Pacific Hepatocellular Carcinoma Trials Group protocol AHCC01 Proceedings of ASCO 2002 Abstr 569"},{"issue":"5","key":"10.1002\/14651858.CD001024.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1053\/jhep.2002.36824","article-title":"High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial","volume":"36","author":"Chow","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0009|cit9","first-page":"Abstr 569","article-title":"High dose tamoxifen versus placebo for inoperable hepatocellular carcinoma: Asia-Pacific Hepatocellular Carcinoma Trials Group protocol AHCC01","volume":"21","author":"Chow","year":"2001","journal-title":"Proceedings of ASCO"},{"issue":"9121","key":"10.1002\/14651858.CD001024.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(98)01259-8","article-title":"Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial","volume":"352","author":"Gallo","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD001024.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2174\/1381612024607063","article-title":"Tamoxifen in the treatment of hepatocellular carcinoma: 5 year results of the CLIP-1 multicentre randomised controlled trial","volume":"8","author":"Perrone","year":"2002","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0012|cit12","unstructured":"Pignata S Izzo F Farinati G Palmieri M Belli L Manzione T Role of Tamoxifen (TM) in the treatment of hepatocellular carcinoma (HCC). Results form the CLIP-1 randomized trial Proceedings of ASCO 1998 Abstr 986"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Coll S Sola R Vila MC Andreu M Bory F Vazquez D Treatment with tamoxifen in patients with advanced hepatocellular carcinoma. Results of a randomized placebo controlled trial Hepatology 1995 1191A","DOI":"10.1016\/0270-9139(95)95338-8"},{"issue":"2","key":"10.1002\/14651858.CD001024.pub2-BIB0014|cit14","first-page":"66","article-title":"Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma","volume":"26","author":"Elba","year":"1994","journal-title":"Italian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD001024.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1572-0241.2000.01688.x","article-title":"Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study","volume":"95","author":"Liu","year":"2000","journal-title":"American Journal of Gastroenterology."},{"key":"10.1002\/14651858.CD001024.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Martinez Cerezo FJ Tomas A Donoso L Enriquez J Balanzo J Guarner C Tamoxifen improves survival in patients with advanced hepatocellular carcinoma (HCC) Journal of Hepatology 1991 S51 00221634","DOI":"10.1016\/0168-8278(91)91194-L"},{"issue":"6","key":"10.1002\/14651858.CD001024.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0168-8278(05)80138-2","article-title":"Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma","volume":"20","author":"Martinez Cerezo","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD001024.pub2-BIB0018|cit18","first-page":"1213","article-title":"Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma","volume":"71","author":"Melia","year":"1987","journal-title":"Cancer Treatment Reports"},{"issue":"3","key":"10.1002\/14651858.CD001024.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00004836-199804000-00010","article-title":"Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma","volume":"26","author":"Riestra","year":"1998","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD001024.pub2-BIB0020|cit20","first-page":"1","article-title":"Effects of tamoxifen on the survival of patients with advanced hepatocellular carcinoma","volume":"14","author":"Das","year":"1999","journal-title":"Journal of the Institute of Postgraduate Medical Research"},{"issue":"3","key":"10.1002\/14651858.CD001024.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0168-8278(90)90211-9","article-title":"Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen","volume":"11","author":"Farinati","year":"1990","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD001024.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF01296419","article-title":"Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma","volume":"37","author":"Farinati","year":"1992","journal-title":"Digestive Diseases & Sciences"},{"issue":"suppl 4","key":"10.1002\/14651858.CD001024.pub2-BIB0023|cit23","first-page":"249A","article-title":"A multicenter randomized trial of anti-androgenic (AA) treatment (leuproprelin+ flutamide+ tamoxifen vs tamoxifen) in patients with unresectable hepatocellular carcinoma (HCC)","volume":"28","author":"Group d`Etude et de traitment de carcinoma hepatocellulaire","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD001024.pub2-BIB0024|cit24","first-page":"1535","article-title":"Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial","volume":"21","author":"Manesis","year":"1995","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD001024.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial","volume":"29","author":"Pelletier","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD001024.pub2-BIB0026|cit26","first-page":"1782","article-title":"Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support","volume":"35","author":"Raoul","year":"1994","journal-title":"Journal of Nuclear Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001024.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00042737-200012030-00004","article-title":"Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma","volume":"12","author":"Schachschal","year":"2000","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD001024.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00000421-199306000-00004","article-title":"Chemohormonal therapy of unresectable hepatocellular carcinoma","volume":"16","author":"Uchino","year":"1993","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0039-6060(97)90317-2","article-title":"Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection","volume":"121","author":"Jonas","year":"1997","journal-title":"Surgery"},{"issue":"11","key":"10.1002\/14651858.CD001024.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001024.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0033|cit33","article-title":"Hepatobiliary neoplasms","volume-title":"Cancer: principles and practice of oncology","author":"Lotze","year":"1993"},{"issue":"2","key":"10.1002\/14651858.CD001024.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2036.1998.00286.x","article-title":"Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis?","volume":"12","author":"Mathurin","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"issue":"9198","key":"10.1002\/14651858.CD001024.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"9061","key":"10.1002\/14651858.CD001024.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","article-title":"Mortality by causes for eight regions of the world: global burden of disease study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD001024.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000658-199008000-00006","article-title":"Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas","volume":"212","author":"Nagasue","year":"1990","journal-title":"Annual Surgery"},{"issue":"5","key":"10.1002\/14651858.CD001024.pub2-BIB0039|cit39","first-page":"918","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients","volume":"56","author":"Okuda","year":"1984","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD001024.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform Meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001024.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD001024.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008285123736","article-title":"Treatment of hepatocellular carcinoma: a systematic review of randomised controlled trials","volume":"8","author":"Simonetti","year":"1997","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD001024.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.20963","article-title":"Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review","volume":"103","author":"Nowak","year":"2005","journal-title":"Cancer"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001024.pub3","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001024.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:59:08Z","timestamp":1628542748000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001024.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2004,7,19]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001024.pub2","relation":{"withdrawal":[{"id-type":"doi","id":"10.1002\/14651858.CD001024.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,19]]}}}